Deerfield Management Honors AML Research Innovators
Deerfield Management, along with the Deerfield Foundation, has announced the recipient of the prestigious American Society of Hematology (ASH) Peter Steelman Scholar Award. This recognition will be awarded to Dr. Gabriele Casirati for his significant contributions to the field of Acute Myeloid Leukemia (AML) research, coinciding with Deerfield's third annual AML Summit.
Who is Dr. Gabriele Casirati?
Dr. Gabriele Casirati is a dedicated hematologist and instructor at renowned medical institutions, focusing on innovative immune engineering strategies for treating acute leukemias. His cutting-edge research aims at enhancing targeted immunotherapies, ultimately improving the prognosis for patients dealing with blood cancers. Dr. Casirati's work, particularly in developing gene-editing approaches, shows promise in making treatments like bone marrow transplants and CAR-T cell therapies safer and more effective for patients.
Acknowledgments from Colleagues
In acknowledging Dr. Casirati's achievements, Dr. Ross L. Levine of Memorial Hospital emphasized the importance of honoring the legacy of Peter Steelman while recognizing exceptional talent. "Our hope is that this award will inspire further breakthroughs in AML treatment, ultimately benefiting those affected by this disease," Levine stated.
About the AML Summit
This year's AML Summit promises to deliver invaluable insights from leading experts within the field. The keynote address will be given by Dr. Ravindra Majeti, who will discuss his research on leukemia stem cells, a crucial element in understanding how to treat human hematologic malignancies effectively. Dr. Majeti expressed excitement about participating in this collaborative effort to address pressing challenges in AML.
Event Details
The AML Summit is scheduled for Tuesday, October 7, and will occur at a Deerfield-affiliated healthcare innovation campus. This summit is a platform for showcasing the latest clinical initiatives and research advancements in AML, diving deeper into the strategies currently reshaping AML treatment.
Featured Speakers at the Summit
- Dr. Ross Levine, a prominent leukemia specialist and Chair of the AML Summit.
- Dr. Ned Sharpless, renowned physician, scientist, and former Director of the National Cancer Institute.
- Dr. Konstantinos Tzelepis, a leading Principal Investigator focusing on stem cell research.
- Dr. Eirini Papapetrou, a well-respected oncologist dedicated to advancements in blood cancer therapies.
- Dr. Marina Konopleva, a professor at Montefiore Einstein Comprehensive Cancer Center working on innovative cancer treatments.
- Dr. Alex Kentsis, an expert in developmental oncology at Memorial Sloan Kettering Cancer Center.
- Dr. Britta Will, an Associate Professor balancing medical oncology and research.
Understanding Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a significant health challenge marked by the uncontrollable growth of abnormal white blood cells, inhibiting normal functions of the bone marrow. This type of leukemia is most commonly diagnosed among adults, making research and treatment innovations a high priority. The American Cancer Society projects that thousands will confront this diagnosis each year, underscoring the urgency for enhanced research efforts.
The ASH Peter Steelman Scholar Award
This award, crafted by Deerfield Management and the Deerfield Foundation in alliance with ASH, supports emerging research directly focused on AML. The recognition aims to ease the transition for researchers moving toward independent careers. It grants extensive benefits, including funding for the annual ASH meeting, invitations to exclusive Deerfield events, and fostering ongoing collaborations.
Commemorating Peter Steelman
The ASH Peter Steelman Scholar Award is named in honor of Peter Steelman, acknowledging his remarkable influence at Deerfield. He was known for his support of innovative research and his dedication to fostering relationships within the academic realm, which now spans a vast network of leading institutions.
About the Deerfield Foundation
The Deerfield Foundation is a not-for-profit organization that aims to improve health and promote equity through impactful partnerships since its founding. By supporting initiatives that advance children’s health care and research, the foundation remains committed to its mission to enhance the quality of lives.
About Deerfield Management
With a strong focus on healthcare advancements, Deerfield Management operates as an investment firm dedicated to connecting innovative ideas and capital in meaningful ways. Their approach fosters inclusive practices aimed at accelerating breakthroughs in health care, creating a more promising future for patients everywhere.
Contact Information
For inquiries:
Contact: Julianna Santamaria
Manager, Deerfield Foundation
Frequently Asked Questions
What is the AML Summit?
The AML Summit is an annual gathering of industry experts discussing advancements in Acute Myeloid Leukemia research and treatment.
Who was awarded the ASH Peter Steelman Scholar Award?
Dr. Gabriele Casirati received the ASH Peter Steelman Scholar Award for his significant contributions to AML research.
What does the ASH Peter Steelman Scholar Award support?
The award supports research in AML and provides resources for researchers transitioning to independent careers.
Who are some featured speakers at the AML Summit?
Featured speakers include Dr. Ross Levine, Dr. Ned Sharpless, and Dr. Ravindra Majeti among others.
What is Acute Myeloid Leukemia?
AML is a type of cancer affecting the bone marrow, leading to the production of abnormal white blood cells.
